120 related articles for article (PubMed ID: 8996540)
1. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
Fazeny B; Baur M; Prohaska M; Hudec M; Kremnitzer M; Meryn S; Huber H; Grunt T; Tuchmann A; Dittrich C
J Cancer Res Clin Oncol; 1997; 123(1):45-52. PubMed ID: 8996540
[TBL] [Abstract][Full Text] [Related]
2. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Jacobi CA; Siderow A; Zieren J; Zieren HU; Müller JM
Chirurg; 1999 Jun; 70(6):694-9. PubMed ID: 10427457
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
[TBL] [Abstract][Full Text] [Related]
4. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.
Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG
Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789
[TBL] [Abstract][Full Text] [Related]
5. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
6. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Zieren HU; Jacobi CA; Müller JM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
8. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
9. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
11. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
Philip PA; Carmichael J; Tonkin K; Buamah PK; Britton J; Dowsett M; Harris AL
Br J Cancer; 1993 Feb; 67(2):379-82. PubMed ID: 8431370
[TBL] [Abstract][Full Text] [Related]
12. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
14. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
Bajetta E; Catena L; Procopio G; Bichisao E; Ferrari L; Della Torre S; De Dosso S; Iacobelli S; Buzzoni R; Mariani L; Rosai J
Ann Oncol; 2005 Aug; 16(8):1374-80. PubMed ID: 15939719
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
16. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
17. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Asbury RF; Brunetto VL; Lee RB; Reid G; Rocereto TF;
Am J Clin Oncol; 2002 Dec; 25(6):557-60. PubMed ID: 12477997
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
